Literature DB >> 32038784

Association of the G134A and G184C Polymorphisms in the CYP1A1 Gene with Lung Cancer Incidence.

Doug-Young Ryu1, Mingai Huang2, Changbo Park1, Soo Im Chang1, Ruth Im2, Seong-Jin Choi2, Na-Young Kim2, In Won Park2, Byoung Whui Choi2, Jae Yeol Kim2, Jong Wook Shin2, Jae Chul Choi2, Byung-Sun Choi2, Jung-Duck Park2.   

Abstract

The G184C and G134A single nucleotide polymorphisms (SNPs) of the CYP1A1 gene result in Ala62Pro and Gly45Asp substitutions, respectively. Here, we tested whether these SNPs are associated with an alteration in lung cancer incidence. We examined 80 Korean subjects with lung cancer and 240 age- and sex-matched controls. For each subject, the CYP1A1 gene was PCR amplified and sequenced. We observed that the odds ratio (OR) for lung cancer was 3.37 higher in subjects with the G184C polymorphism than in controls (95% confidence interval (CI), 0.89~12.73, P = 0.07). In contrast, the OR for lung cancer was 1.23 in subjects with the G134A polymorphism compared to controls (95% CI, 0.68~2.20, P = 0.49). The G184C polymorphism exacerbated the effects of smoking on lung cancer development. Gene-smoking interaction analyses revealed that past or present smokers with the G184C polymorphism had a higher incidence of lung cancer (OR, 24.72; 95% CI, 4.48~136.31; P < 0.01) than control smokers (OR, 6.65; 95% CI, 2.72~16.28; P < 0.01). However, there was only a slight difference in the ORs for lung cancer between control smokers and smokers with the G134A polymorphism. These findings suggest that the G184C polymorphism, but not the G134A polymorphism, is associated with an increased risk of lung cancer. © Korean Society of Toxicology 2008.

Entities:  

Keywords:  Ala62Pro; CYP1A1; G134A; G184C; Gly45Asp; Lung cancer; Single nucleotide polymorphism

Year:  2008        PMID: 32038784      PMCID: PMC7006316          DOI: 10.5487/TR.2008.24.2.109

Source DB:  PubMed          Journal:  Toxicol Res        ISSN: 1976-8257


  15 in total

1.  Detection of known and two novel (M331I and R464S) missense mutations in the human CYP1A1 gene in a French Caucasian population.

Authors:  D Chevalier; D Allorge; J M Lo-Guidice; C Cauffiez; M Lhermitte; J J Lafitte; F Broly
Journal:  Hum Mutat       Date:  2001-04       Impact factor: 4.878

2.  Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene.

Authors:  S Hayashi; J Watanabe; K Nakachi; K Kawajiri
Journal:  J Biochem       Date:  1991-09       Impact factor: 3.387

3.  Association of Ile462Val (Exon 7) polymorphism of cytochrome P450 IA1 with lung cancer in the Asian population: further evidence from a case-control study in Okinawa.

Authors:  H Sugimura; K Wakai; K Genka; K Nagura; H Igarashi; K Nagayama; A Ohkawa; S Baba; B J Morris; S Tsugane; Y Ohno; C Gao; Z Li; T Takezaki; K Tajima; T Iwamasa
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1998-05       Impact factor: 4.254

4.  Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms.

Authors:  J Smart; A K Daly
Journal:  Pharmacogenetics       Date:  2000-02

5.  Msp-1 polymorphism detected with a cDNA probe for the P-450 I family on chromosome 15.

Authors:  N K Spurr; A C Gough; K Stevenson; C R Wolf
Journal:  Nucleic Acids Res       Date:  1987-07-24       Impact factor: 16.971

6.  A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility.

Authors:  I Cascorbi; J Brockmöller; I Roots
Journal:  Cancer Res       Date:  1996-11-01       Impact factor: 12.701

Review 7.  Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers.

Authors:  H Bartsch; U Nair; A Risch; M Rojas; H Wikman; K Alexandrov
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-01       Impact factor: 4.254

8.  CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls.

Authors:  Paolo Vineis; Fabrizio Veglia; Simone Benhamou; Dorota Butkiewicz; Ingolf Cascorbi; Margie L Clapper; Vita Dolzan; Aage Haugen; Ari Hirvonen; Magnus Ingelman-Sundberg; Masahiro Kihara; Chikako Kiyohara; Pierre Kremers; Loic Le Marchand; Susumu Ohshima; Roberta Pastorelli; Agneta Rannug; Marjorie Romkes; Bernadette Schoket; Peter Shields; Richard C Strange; Isabelle Stucker; Haruhiko Sugimura; Seymour Garte; Laura Gaspari; Emanuela Taioli
Journal:  Int J Cancer       Date:  2003-05-01       Impact factor: 7.396

9.  Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450.

Authors:  M E McManus; W M Burgess; M E Veronese; A Huggett; L C Quattrochi; R H Tukey
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701

10.  Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.

Authors:  Joseph F Solus; Brenda J Arietta; James R Harris; David P Sexton; John Q Steward; Chara McMunn; Patrick Ihrie; Janelle M Mehall; Todd L Edwards; Elliott P Dawson
Journal:  Pharmacogenomics       Date:  2004-10       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.